Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 35, 2009, Pages 14942-14947

  Stegbauer, Johannes ^a   Lee, De Hyung ^b   Seubert, Silvia ^b   Ellrichmann, Gisa ^b   Manzel, Arndt ^b   Kvakan, Heda ^c   Muller, Dominik N ^c   Gaupp, Stefanie ^b   Rump, Lars Christian ^a   Gold, Ralf ^b   Linker, Ralf A ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Antigen presenting cell; Blood pressure; Chemokine; Multiple sclerosis

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; CD11B ANTIGEN; ENALAPRIL; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN P 15095; HYDRALAZINE; LOSARTAN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RENIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD PRESSURE REGULATION; CELL MIGRATION; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; HYPERTENSION; IMMUNE RESPONSE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; UPREGULATION;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIGEN-PRESENTING CELLS; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINES; ENALAPRIL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FUMARATES; LOSARTAN; MICE; MICE, INBRED C57BL; MYELIN-ASSOCIATED GLYCOPROTEIN; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 70349273755     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0903602106     Document Type: Article

References (32)

1. Goodfriend TL, Elliott ME, Catt KJ (1996) Angiotensin receptors and their antagonists. N Engl J Med 334:1649-1654.
2. Crowley SD, et al. (2006) Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 103:17985-17990.
3. Combadiere C, et al. (2008) Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117:1649-1657.
4. Griendling KK, Lassegue B, Alexander RW (1996) Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 36:281-306. (Pubitemid 26169900)
5. Muller DN, et al. (2002) Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 161:1679-1693. (Pubitemid 35265527)
6. Guzik TJ, et al. (2007) Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204:2449-2460. (Pubitemid 47529329)
7. Dragun D, et al. (2005) Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352:558-569. (Pubitemid 40204669)
8. Werner C, et al. (2008) RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol 97:418-431.
9. Clasen R, et al. (2005) PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46:137-143. (Pubitemid 40946504)
10. Herrero-Herranz E, Pardo LA, Gold R, Linker RA (2008) Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis 30:162-173.
11. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD (2005) Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11:335-339. (Pubitemid 40460563)
12. Muller DN, Derer W, Dechend R (2008) Aliskiren - mode of action and preclinical data. J Mol Med 86:659-662.
13. Nishida M, et al. (2002) Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 110:1859-1868. (Pubitemid 36076493)
14. Crowley SD, et al. (2009) Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 119:943-953.
15. Nahmod KA, et al. (2003) Control of dendritic cell differentiation by angiotensin II. FASEB J 17:491-493.
16. Tacke F, et al. (2007) Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 117:185-194. (Pubitemid 46048465)
17. Soehnlein O, et al. (2005) ACE inhibition lowers angiotensin-II-induced monocyte adhesion to HUVEC by reduction of p65 translocation and AT 1 expression. J Vasc Res 42:399-407. (Pubitemid 41368958)
18. Schmeisser A, et al. (2004) ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. Biochem Biophys Res Commun 325:532-540. (Pubitemid 39458027)
19. Wolf G, Schneider A, Helmchen U, Stahl RA (1998) AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Exp Nephrol 6:112-120. (Pubitemid 28140992)
20. Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T (1997) Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. J Biol Chem 272:31092-31099. (Pubitemid 27527558)
21. Ruiz-Ortega M, et al. (1998) Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 161:430-439. (Pubitemid 28285552)
22. Muller DN, et al. (2001) Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage. FASEB J 15:1822-1824.
23. Marchesi C, Paradis P, Schiffrin EL (2008) Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 29:367-374.
24. Constantinescu CS, Ventura E, Hilliard B, Rostami A (1995) Effects of the angiotensin converting enzyme inhibitor captopril on experimental autoimmune encephalomyelitis. Immunopharmacol Immunotoxicol 17:471-491.
25. Schulze-Topphoff U, et al. (2009) Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 15:788-793.
26. Okunuki Y, et al. (2009) Angiotensin II type 1 receptor blocker telmisartan suppresses experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 50:2255-2261.
27. Martin MF, et al. (1984) Captopril: a new treatment for rheumatoid arthritis? Lancet 1:1325-1328. (Pubitemid 14111108)
28. Constantinescu CS, Goodman DB, Grossman RI, Mannon LJ, Cohen JA (1997) Serum angiotensin-converting enzyme in multiple sclerosis. Arch Neurol 54:1012-1015. (Pubitemid 27330410)
29. Linker RA, et al. (2002) CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 8:620-624.
30. Goetzl EJ, et al. (2001) Enhanced delayed-type hypersensitivity and diminished immediate- type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci USA 98:13854-13859.
31. Linker RA, et al. (2008) Leukemia inhibitory factor deficiency modulates the immune response and limits autoimmune demyelination: anewrole for neurotrophic cytokines in neuroinflammation. J Immunol 180:2204-2213.
32. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408. (Pubitemid 34164012)